Uses
NURTEC ODT is a calcitonin gene-related peptide receptor antagonist indicated for the: • acute treatment of migraine with or without aura in adults. • preventive treatment of episodic migraine in adults
Source: US FDA prescribing information
- Presentations
- 1
- Brands
- 1
- Manufacturers
- 1
- Available from stock
- 0
Rimegepant is a calcitonin gene-related peptide receptor antagonist indicated for the acute treatment of migraine with or without aura in adults, among other approved uses. It is available as orally disintegrating tablets. MedsAcross supplies Rimegepant for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Key facts
- Pharmacological class
- Calcitonin Gene-related Peptide Receptor Antagonist, Calcitonin Gene-related Peptide Receptor Antagonists
- ATC classification
- N02CD06 Rimegepant · Antimigraine, subgroup N02CD
- US FDA first approval
- 27 February 2020
- EU status
- Authorised
- Orphan designation
- No
- WHO essential medicine
- Not recorded
- India (CDSCO)
- Not yet confirmed against CDSCO approval lists
- Routes
- Oral
- Dosage forms
- Orally disintegrating tablet
- Identifiers
- UNII 997WVV895XCAS 1289023-67-1DrugBank DB12457Q27272184
Clinical information
From the regulator-approved product information. Each section names its source.
How it works
Rimegepant is a calcitonin gene-related peptide receptor antagonist.
Source: US FDA prescribing information
Dosing overview
• Recommended dosage for acute treatment of migraine: 75 mg taken orally, as needed. • The safety of using more than 18 doses in a 30-day period has not been established. • Recommended dosage for preventive treatment of episodic migraine: 75 mg taken orally every other day. • The maximum dose in a 24-hour period is 75 mg. • NURTEC ODT can be taken with or without food.
Source: US FDA prescribing information
Contraindications
NURTEC ODT is contraindicated in patients with a history of hypersensitivity reaction to rimegepant, NURTEC ODT, or any of its components. Reactions have included anaphylaxis and delayed serious hypersensitivity. Patients with a history of hypersensitivity reaction to rimegepant, NURTEC ODT, or to any of its components.
Source: US FDA prescribing information
Warnings and precautions
• Hypersensitivity Reactions: If a serious hypersensitivity reaction occurs, discontinue NURTEC ODT and initiate appropriate therapy. Severe hypersensitivity reactions have included anaphylaxis, dyspnea, and rash, and can occur days after administration. • Hypertension: New-onset or worsening of pre-existing hypertension may occur. • Raynaud’s Phenomenon: New-onset or worsening of pre-existing Raynaud’s phenomenon may occur.
Source: US FDA prescribing information
Side effects
The following clinically significant adverse reactions are discussed in greater detail in other sections of the labeling: • Hypersensitivity Reactions • Hypertension • Raynaud’s Phenomenon • Acute treatment of migraine: the adverse reaction reported in ≥1% of patients treated with NURTEC ODT is nausea. • Preventive treatment of episodic migraine: adverse reactions reported in ≥2% for rimegepant and ≥1% higher than placebo are nausea and abdominal pain/dyspepsia.
Source: US FDA prescribing information
Interactions
• Strong CYP3A4 Inhibitors: Avoid concomitant administration. • Moderate CYP3A4 Inhibitors: Avoid another dose within 48 hours when administered with a moderate CYP3A4 inhibitor. • Strong and Moderate CYP3A Inducers: Avoid concomitant administration. • Potent Inhibitors of P-gp: Avoid another dose of NURTEC ODT within 48 hours when administered with a potent P-gp inhibitor.
Source: US FDA prescribing information
Storage
Store NURTEC ODT at controlled room temperature, 20°C to 25°C (68°F to 77°F), with excursions permitted between 15°C to 30°C (59°F to 86°F).
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
All presentations
1 presentations of Rimegepant, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Nurtec ODT 75 mg orally disintegrating tabletOral | Pfizer Laboratories | US FDA | Available on request |
Brands by market
1 brand names across 1 markets.
United States
Manufacturers
Regulatory status
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
Questions and answers
Is Rimegepant available for export from India?
Yes, on request. MedsAcross lists 1 presentations of Rimegepant and sources them for licensed hospitals, importers and physicians against valid import documents.
What brand names does Rimegepant have?
The catalogue lists 1 brand names for Rimegepant, including Nurtec ODT.
Is Rimegepant approved by the US FDA?
Yes. The US FDA first approved Rimegepant on 27 February 2020, according to Drugs@FDA.
Is Rimegepant authorised in the European Union?
Yes. Rimegepant has a central EU marketing authorisation (status: authorised), according to European Medicines Agency data.
Does Rimegepant need cold chain shipping?
No listed presentation of Rimegepant is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Which ATC class is Rimegepant in?
Rimegepant is classified under ATC code N02CD06 (Rimegepant).
References
- NURTEC ODT prescribing information (Pfizer Laboratories). U.S. National Library of Medicine, DailyMed. Retrieved 4 June 2026
- Vydura: European public assessment report (EPAR). European Medicines Agency. Retrieved 22 October 2026
Request Rimegepant for export supply
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.